Every tenth malignant solid tumor attributed to overweight and alcohol consumption: a population-based cohort study
Recent studies have shown that some four in ten cancers are attributable to a few key risk factors. The aim of this study was to estimate cohort-based population attributable fractions (PAFs) in Finland for potentially modifiable cancer risk factors. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 18, 2023 Category: Cancer & Oncology Authors: Karri Sepp ä, Sanna Heikkinen, Heidi Ryynänen, Demetrius Albanes, Johan G Eriksson, Tommi Härkänen, Pekka Jousilahti, Paul Knekt, Seppo Koskinen, Satu Männistö, Ossi Rahkonen, Harri Rissanen, Nea Malila, Maarit Laaksonen, Janne Pitkäniemi, the METC Tags: Original Research Source Type: research
Advancing Equitable and Personalized Cancer Care: Novel Applications and Priorities of Artificial Intelligence for Fairness and Inclusivity in the Patient Care Workflow
Patient care workflows are highly multimodal and intertwined: the intersection of data outputs provided from different disciplines and in different formats remains one of the main challenges of modern oncology. Artificial Intelligence (AI) has the potential to revolutionize the current clinical practice of oncology owing to advancements in digitalization, database expansion, computational technologies, and algorithmic innovations that facilitate discernment of complex relationships in multimodal data. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 18, 2023 Category: Cancer & Oncology Authors: Marisa Cobanaj, Chiara Corti, Edward C. Dee, Lucas McCullum, Laura Boldrini, Ilana Schlam, Sara M. Tolaney, Leo A. Celi, Giuseppe Curigliano, Carmen Criscitiello Tags: Review Source Type: research
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: the EORTC 1608 STEAM trial
Zotiraciclib (TG02) is an oral multi-cyclin dependent kinase (CDK) inhibitor thought to inhibit tumor growth via CDK-9-dependent depletion of survival proteins such as c-MYC and MCL-1 which are frequently overexpressed in glioblastoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 18, 2023 Category: Cancer & Oncology Authors: Emilie Le Rhun, Thierry Gorlia, J örg Felsberg, Joost Jongen, Claude-Alain Maurage, François Ducray, Dorothee Gramatzki, Peter Hau, Olivier L. Chinot, Matthias Preusser, Stephanie Cartalat, Patrick Roth, Martin van den Bent, Julia Furtner, Maike Collien Tags: Clinical Trial Source Type: research
Letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study
To the editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 18, 2023 Category: Cancer & Oncology Authors: Wentian Lu Tags: Letter to the Editor Source Type: research
Objective Response Rate and Progression-Free Survival as Surrogates for Overall Survival Treatment Effect: A Meta-analysis across Diverse Tumour Groups and Contemporary Therapies
Overall survival (OS) results from randomized control trials (RCT) provide the strongest evidence for efficacy of anti-cancer treatments but can take a considerable amount of time to mature. Progression free survival (PFS) and objective response rate (ORR) are used as an early surrogate of OS treatment effect however their validity remains unclear. Our study aims to comprehensively evaluate ORR and PFS as surrogates for OS treatment effect across tumor groups and treatment types. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 18, 2023 Category: Cancer & Oncology Authors: Adel Shahnam, Nadia Hitchen, Udit Nindra, Sathya Manoharan, Jayesh Desai, Ben Tran, Benjamin Solomon, Stephen J Luen, Rina Hui, Ashley M Hopkins, Michael J Sorich Tags: Original Research Source Type: research
Editorial Board
(Source: European Journal of Cancer)
Source: European Journal of Cancer - December 15, 2023 Category: Cancer & Oncology Source Type: research
Immunotherapy in mismatch repair-deficient metastatic colorectal cancer – Outcome and novel predictive markers
This study aims to assess predictive markers for response to immunotherapy in dMMR/MSI-H metastatic colorectal cancer (mCRC) patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 15, 2023 Category: Cancer & Oncology Authors: Amos Stemmer, Ofer Margalit, Victoria Serpas, Gal Strauss, Jane Thomas, Preksha Shah, Noam Tau, Keren Levanon, Einat Shacham-Shmueli, Scott Kopetz, Michael Overman, Ben Boursi Tags: Original research Source Type: research
Immunotherapy in mismatch repair-deficient metastatic colorectal cancer –outcome and novel predictive markers
This study aims to assess predictive markers for response to immunotherapy in dMMR/MSI-H metastatic colorectal cancer (mCRC) patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 15, 2023 Category: Cancer & Oncology Authors: Amos Stemmer, Ofer Margalit, Victoria Serpas, Gal Strauss, Jane Thomas, Preksha Shah, Noam Tau, Keren Levanon, Einat Shacham-Shmueli, Scott Kopetz, Michael Overman, Ben Boursi Tags: Original Research Source Type: research
Precision medicine for KRAS Wild-Type pancreatic adenocarcinomas
KRAS mutation is the most common molecular alteration in pancreatic adenocarcinoma (PDAC), and around 10% of patients harbor KRAS wild-type tumors (KRASWT). (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 15, 2023 Category: Cancer & Oncology Authors: Imen Ben-Ammar, Adrien Rousseau, R émy Nicolle, Anthony Tarabay, Valérie Boige, Marine Valery, Thomas Pudlarz, David Malka, Maximiliano Gelli, Elena Fernandez-De-Sevilla, Alina Fuerea, Marie-Laure Tanguy, Etienne Rouleau, Rémy Barbe, Jacques R.R Mathie Tags: Original Research Source Type: research
Response to the Letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study
To the editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 15, 2023 Category: Cancer & Oncology Authors: Najib Ben Khaled, Bernhard M örtl, Dominik Beier, Florian P. Reiter, Dorota Pawlowska-Phelan, Andreas Teufel, Daniel Rössler, Daniel Schwade, Alexander Philipp, Ilja Kubisch, Ursula Ehmer, Andreas Geier, Christian M. Lange, Julia Mayerle, Karin Berger, Source Type: research
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer
In MONALEESA-2, addition of ribociclib to letrozole resulted in significantly longer progression-free survival (PFS) in postmenopausal women with HR+HER2 − advanced breast cancer (ABC). RIBociclib for the treatment of advanCed breast CAncer (RIBECCA) study investigated ribociclib plus letrozole in a patient population reflecting routine clinical practice. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 14, 2023 Category: Cancer & Oncology Authors: Peter A. Fasching, Thomas Decker, Andreas Hartkopf, Arnd Nusch, Bernhard J. Heinrich, Christian Kurbacher, Roswitha Fuchs, Hans Tesch, Petra Krabisch, Jens Huober, Sherko Kuemmel, Sara Brucker, Wolfgang Janni, Andreas Schneeweiss, Martin Schuler, Tanja Fe Tags: Original Research Source Type: research
Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting
To describe the attitudes of healthcare professionals and drug regulators about progression-free survival (PFS) as efficacy endpoint in clinical trials with patients with advanced cancer and to explore to what extent these attitudes influence the willingness to trade between PFS and toxicity. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 14, 2023 Category: Cancer & Oncology Authors: Douwe Postmus, Saskia Litiere, Jan Bogaerts, Jurjen Versluis, Jan Cornelissen, Francesco Pignatti Tags: Original Research Source Type: research
Risk factors for early-onset pancreatic ductal adenocarcinoma: a systematic literature review
Emerging cancer trends suggest an increase in pancreatic cancer incidence in individuals younger than its typical age of onset, potentially reflecting changes in population exposures and lifestyles. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Sreenivasa R. Chandana, Laura Woods, Fiona Maxwell, Ruth Gandolfo, Tanios Bekaii-Saab Tags: Review Source Type: research
Quantitative Expression of Oestrogen Receptor in Breast Cancer: Clinical and Molecular Significance
This study aimed to assess the clinical and molecular consequences of ER heterogeneity with respect to ET-response. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Shorouk Makhlouf, Cecily Quinn, Michael Toss, Mansour Alsaleem, Nehal M Atallah, Asmaa Ibrahim, Catrin S Rutland, Nigel P. Mongan, Emad A Rakha Tags: Original Research Source Type: research
PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Eva Elleb æk, Shawez Khan, Lars Bastholt, Henrik Schmidt, Charlotte Aaquist Haslund, Marco Donia, Inge Marie Svane Source Type: research
